Forging ahead for 23 years: from the Human Genome Project to the SpatioTemporal Omics Consortium; Internships and Scholarships for Studying in Serbia and China

Abstract:

PART I:

In this part, the CEO of BGI Group will be introducing the history and the advanced technologies of BGI.

In 1997, Prof. Yang Huanming, Yu Jun, Wang Jian and others proposed a set of forward-looking strategic ideas on China's participation in the Human Genome Project (HGP) in Zhangjiajie, Hunan. This gave birth to the development and future of Chinese genomics. Then in 1999, BGI was established for the Human Genome Project.

Stereo-seq technology is the latest breakthrough from BGI-Research to help scientists explore the mysteries of life like never before. Scientists have attempted to understand how cells work by studying the tiniest of details and understanding how each cell works in larger biological systems.

Technologies that allowed scientists to see detail at the nano-level could not provide similar insight for a wider field of vision. With the development of BGI’s Stereo-seq technology, scientists no longer have to conduct thousands and even tens of thousands of experiments to create a coherent spatiotemporal map of biological systems they are studying. Stereo-seq technology now enables scientists to see a new level of detail and is helping them understand how cells communicate and work in concert with one another across space and time.

PART II:

During this Lecture, the vice dean of BGI College and the executive director of BGI Research Europe will introduce about the internship programs, thesis projects, and scholarships for students at University of Belgrade prepared by BGI.

Come and meet us to discover more about the technologies and opportunities!

 

About company:

Founded in 1999, BGI is one of the world's leading life science and genomics organizations. Following a genomics development model of “research, production and application”, BGI develops businesses in more than 100 countries and regions around the world. Focusing on novel scientific research with a good application value, BGI is dedicated to the research of genomes, tumors, brain science, reproductive health and animal and plant molecular breeding. Since 1999, BGI has published 4086 research papers, including 3565 SCI papers (451 papers in Cell, Nature, New England Journal of Medicine, and Science), with a total citation of 419341. According to 2022 Nature Index, BGI ranks 1st in the life science industry in Asian-Pacific region for 7 successive years and ranks 8th in global life science industry.

With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.